Survival analysis was performed by classifying the present AFP-GC patients into two groups according to the clinicopathological factors as follows; HER2 overexpressed and non-overexpressed groups, female and male, < 70 years and ≥ 70years, lower and upper/middle of tumor location, clinical stage I – III and stage IV, operated and non-operated, < 500ng/ml and ≥ 500ng/ml of serum AFP level, and intestinal/diffuse type and mixed type of histologic subtype classified by Lauren’s classification. This evidence concerns the gene AFP and gastric cancer.